GLP-3/R 10mg
$70.00
GLP-3/R is a next-generation metabolic peptide designed as a triple-agonist for the GLP-1, GIP, and glucagon receptors. Early human trials suggest profound effects on glucose regulation, appetite control, and body-weight reduction.
By targeting three key hormonal pathways simultaneously, GLP-3R represents an evolution beyond single-agonist incretin therapies.
BUY 5 save 5%
BUY 10 save 10%
In stock
Description
Mechanism of Action:
- GLP-1 agonism → enhanced glucose-dependent insulin release, slower gastric emptying, and reduced appetite.
- GIP agonism → amplifies insulin secretion and supports lipid metabolism.
- Glucagon agonism → increases energy expenditure and fat oxidation while preserving lean mass.
Together, these create a comprehensive metabolic response: reduced caloric intake with increased metabolic output.
Research Highlights:
Phase 2 clinical studies (Eli Lilly, 2023) demonstrated average weight reductions >24% over 48 weeks, the largest observed with any metabolic peptide to date.
Significant improvements were seen in insulin sensitivity, triglyceride profiles, and hepatic steatosis markers.
References: PMID 37680170 | 37351205 | Nature Metab 2024
Potential Applications (for research use):
- Obesity and metabolic-syndrome models
- Non-alcoholic fatty-liver disease (NAFLD)
- Insulin-resistance pathways
Stacking Callouts:
May be co-researched with AOD-9604 for enhanced lipolytic targeting or MOTS-C for mitochondrial optimization.
Disclaimer:
For laboratory and research use only. Not for human consumption.
